Regular readers will recall that Dulera® was a legacy Schering-Plough product, FDA approved in 2010. In late 2010, once it controlled Schering-Plough's legacy products -- Merck withdrew its application in the EU for approval of an aersolized fixed dose combo version, for a host of reasons. So it goes:
. . . .The Company has received a civil investigative demand from the U.S. Attorney’s Office, Eastern District of Pennsylvania which requests information relating to the Company’s contracting and pricing of Dulera Inhalation Aerosol with certain pharmacy benefit managers and Medicare Part D plans. The Company is cooperating with the investigation. . . .
Morning, one and all! Onward!
1 comment:
I saw that too last night.....
Post a Comment